Hepatic encephalopathy: investigational drugs in preclinical and early phase development.
Tiziano BalzanoMarta LlansolaYaiza M ArenasPaula Izquierdo-AltarejosVicente FelipoPublished in: Expert opinion on investigational drugs (2023)
A factor limiting the progress of HE treatment is the lack of translation of research advances into clinical trials. Only drugs acting on microbiota or ammonia reduction have been tested in patients. t is urgent to change the mentality on how to approach HE treatment to develop clinical trials to assess drugs acting on the immune system/peripheral inflammation, neuroinflammation or neurotransmission to improve HE.